Skip to main content

6 Result(s)

within Sang-We Kim Remove this filter Medicine & Public Health Remove this filter

and
Your search also matched 15 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you. results, e.g.

Central nervous systemic efficacy of immune checkpoint inhibitors and concordance between intra/extracranial response in non-small cell lung cancer patients with brain metastasis

Include preview-only content

  1. Article

    Open Access

    Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria

    Accurate response parameters are important for patients with brain metastasis (BM) undergoing clinical trials using immunotherapy, considering poorly defined enhancement and variable responses. This study inve...

    Yun Hwa Roh, Ji Eun Park, Sora Kang, Shinkyo Yoon, Sang-We Kim… in Cancer Imaging (2023)

    Download PDF (1745 KB) View Article

  2. Article

    Open Access

    First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors

    CD73 upregulation in tumors leads to local immunosuppression. This phase I, first-in-human study evaluated oleclumab (MEDI9447), an anti-CD73 human IgG1λ monoclonal antibody, alone or with durvalumab in patien...

    Johanna Bendell, Patricia LoRusso, Michael Overman… in Cancer Immunology, Immunotherapy (2023)

    Download PDF (5784 KB) View Article

  3. Article

    Open Access

    Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations

    This study evaluated outcomes among patients with advanced/metastatic non-small-cell lung cancer (NSCLC) treated at Asian centers participating in the global named-patient-use (NPU) program for afatinib.

    Gee-Chen Chang, David Chi-Leung Lam… in International Journal of Clinical Oncology (2021)

    Download PDF (584 KB) View Article

  4. Article

    Open Access

    Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study

    The WEE1 inhibitor adavosertib (AZD1775) has been investigated in Western patients.

    Hidenori Kato, Paul de Souza, Sang-We Kim, Jason D. Lickliter… in Targeted Oncology (2020)

    Download PDF (758 KB) View Article

  5. Article

    Open Access

    First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression

    In the randomized phase IIb LUX-Lung 7 trial, afatinib significantly improved progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with treatment-naïve epidermal growth factor...

    Martin Schuler, Eng-Huat Tan… in Journal of Cancer Research and Clinical On… (2019)

    Download PDF (1949 KB) View Article

  6. Article

    Open Access

    Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

    After publication of this supplement [1, 2], it was brought to our attention that due to an error authors were missing in the following abstracts. This has now been included in this correction.

    Sneha Berry, Nicolas Giraldo, Peter Nguyen… in Journal for ImmunoTherapy of Cancer (2019)

    Download PDF (1085 KB) View Article